Recent Updates — XRTX
XORTX Therapeutics Inc. outlined its planned submission of a Clinical Trial Application (CTA) to Health Canada for the XRx-026 program, which evaluates XORLO, a proprietary formulation of oxypurinol, for treating gout. The filing supports a two-part clinical study, XRX-OXY-102, with Part One intended to accelerate data delivery in support of a planned New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA). The company noted that conducting the initial trial phase in Canada is expected to enhance regulatory strategy efficiency globally. Additionally, XORTX reported receiving increased inquiries from potential commercialization partners for the program but confirmed no agreements have been reached. XORTX Therapeutics Inc. operates as a late-stage clinical pharmaceutical company focused on developing innovative therapies for gout and progressive kidney disease.
XORTX Therapeutics announced it plans to submit an Investigational New Drug (IND) application to the U.S. FDA for its XRx-026 gout program in the fourth quarter of 2026. The submission follows a planned two-part clinical trial, XRX-OXY-102, designed to characterize pharmacokinetics and efficacy using the company's proprietary XORLO formulation of oxypurinol. If successful, XORTX targets an NDA submission approximately one year later. The company estimates the U.S. market opportunity for this therapy at over USD$700 million annually based on prior peak sales data for febuxostat. XORTX Therapeutics is a late-stage clinical pharmaceutical company focused on developing innovative therapies to treat gout and progressive kidney disease.
XORTX Therapeutics Inc. announced the initiation of clinical and commercial manufacturing for XORLO™ (oxypurinol), its proprietary formulation for treating gout, under the XRx-026 program. The company has begun contract production of GMP drug substance using a proprietary synthetic pathway and is working with a partner to manufacture commercial-scale tablets. This activity supports the planned two-part XRX-OXY-102 clinical study and builds validation data intended to support a future New Drug Application (NDA) filing for US FDA marketing approval. The company operates in the pharmaceutical industry, developing therapies for gout and kidney disease.
XORTX Therapeutics terminated its investor relations agreement with IR Agency LLC effective August 7, 2026, rescinding a $2.5 million marketing arrangement originally funded by proceeds from a May 19, 2026 public offering. The company returned the full fee to itself on August 14, 2026 and postponed the program while completing its voluntary delisting from the TSX Venture Exchange, expected September 1, 2026. Additionally, Computershare Investor Services Inc. replaces TSX Trust Company as transfer agent effective September 1, 2026. The filing also corrects a prior omission by disclosing $240,000 in aggregate cash finder’s fees paid for the April 13, 2026 acquisition of Vectus Biosystems Limited’s Renal Anti-Fibrotic Therapeutic Program. XORTX is a late-stage clinical pharmaceutical company developing therapies for gout and progressive kidney disease.
XORTX Therapeutics Inc. filed unaudited condensed interim consolidated financial statements for the six months ended June 30, 2026. The company reported a net loss of $2,499,206 and cash on hand of $994,045. During the period, XORTX completed the acquisition of the VB4-P5 renal anti-fibrotic therapeutic program from Vectus Biosystems Limited for an aggregate deemed value of US$3.0 million, issuing 154,544 common shares and pre-funded warrants valued at $1,871,194. On May 15, 2026, the company raised gross proceeds of $5,000,000 through a public offering of common shares and pre-funded warrants. The filing also notes that XORTX completed a 5-for-1 share consolidation on April 6, 2026, to regain compliance with Nasdaq's minimum bid price requirement. XORTX Therapeutics Inc. is a late-stage clinical pharmaceutical company focused on developing innovative therapies for gout and progressive kidney disease.